X
<

Latest News on the Dentsply Sirona-MIS Acquisition

PART:
1 2
Part 2
Latest News on the Dentsply Sirona-MIS Acquisition PART 2 OF 2

What Are Analysts’ Recommendations for Dentsply Sirona?

Analysts’ recommendations

According to analysts’ consensus estimate, Dentsply Sirona (XRAY) has the potential to return ~11.7% over the next 12 months. Of the recommendations received from 14 brokerage companies in a Bloomberg survey, 43% of the analysts gave Dentsply Sirona a “buy” rating and ~57% gave it a “hold” rating. None of the analysts gave Dentsply Sirona a “sell” rating.

What Are Analysts’ Recommendations for Dentsply Sirona?

Interested in ALGN? Don't miss the next report.

Receive e-mail alerts for new research on ALGN

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

The above chart lists the nine brokerage firms that provided target prices for Dentsply Sirona for the next year. The consensus 12-month target price for the company is $68.7—amounting to an 11.7% return potential. Dentsply Sirona’s price was $61.5 on June 29, 2016. The stock traded at a 52-week high of $65.8 on June 13, 2016, and at a 52-week low of $49.5 on October 2, 2015. Dentsply Sirona’s stock registered an ~19.8% total return in the last 12 months.

Analysts’ 12-month target prices

On May 9, 2016, Goldman Sachs gave Dentsply Sirona a one-year target price of $63—the lowest of all the target prices provided. This target implies a 2.5% return over the next 12 months. Among the other large investment banks, Morgan Stanley gave Dentsply Sirona a one-year target price of $65. This implies a return potential of 5.8% over the next 12 months. The highest one-year target price of $78 was provided by Northcoast Research. It represents a return potential of ~27%.

Peers Zimmer Biomet Holdings (ZBH), Align Technologies (ALGN), and Integra Lifesciences Holdings (IART) have average broker target prices of $128, $87.1, and $79.8, respectively. These figures imply returns of 7.5%, 9.1%, and 2.3%, respectively, in the next 12 months. Investors might want to consider ETFs such as the iShares Russell Mid-Cap ETF (IWR). IWR has ~0.25% exposure to Dentsply Sirona.

X

Please select a profession that best describes you: